| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 103 | 2023 | 1164 | 11.330 |
Why?
|
| Severity of Illness Index | 73 | 2023 | 1113 | 5.610 |
Why?
|
| Movement Disorders | 16 | 2023 | 141 | 2.820 |
Why?
|
| Disability Evaluation | 22 | 2022 | 327 | 2.650 |
Why?
|
| Cognition Disorders | 21 | 2018 | 1011 | 2.630 |
Why?
|
| Hallucinations | 12 | 2023 | 87 | 2.220 |
Why?
|
| Torticollis | 10 | 2023 | 69 | 2.140 |
Why?
|
| Humans | 176 | 2023 | 29337 | 2.070 |
Why?
|
| Neuropsychological Tests | 26 | 2022 | 1251 | 1.950 |
Why?
|
| Tremor | 12 | 2023 | 141 | 1.720 |
Why?
|
| Dyskinesia, Drug-Induced | 6 | 2023 | 54 | 1.660 |
Why?
|
| Placebo Effect | 3 | 2020 | 25 | 1.640 |
Why?
|
| Telemedicine | 3 | 2022 | 99 | 1.610 |
Why?
|
| Psychiatric Status Rating Scales | 15 | 2021 | 343 | 1.590 |
Why?
|
| Brain | 15 | 2023 | 1689 | 1.540 |
Why?
|
| Psychometrics | 18 | 2020 | 262 | 1.460 |
Why?
|
| Magnetic Resonance Imaging | 21 | 2020 | 1221 | 1.370 |
Why?
|
| Aged | 64 | 2022 | 9448 | 1.300 |
Why?
|
| Middle Aged | 62 | 2022 | 9823 | 1.230 |
Why?
|
| Neurologic Examination | 9 | 2016 | 146 | 1.210 |
Why?
|
| Sleep Wake Disorders | 9 | 2021 | 148 | 1.200 |
Why?
|
| Cognitive Dysfunction | 8 | 2018 | 938 | 1.200 |
Why?
|
| Reproducibility of Results | 35 | 2023 | 788 | 1.160 |
Why?
|
| Research Design | 3 | 2020 | 212 | 1.160 |
Why?
|
| Societies, Medical | 12 | 2022 | 190 | 1.150 |
Why?
|
| Male | 75 | 2022 | 15621 | 1.120 |
Why?
|
| Female | 77 | 2022 | 16197 | 1.120 |
Why?
|
| Deep Brain Stimulation | 7 | 2022 | 74 | 1.080 |
Why?
|
| Mental Status and Dementia Tests | 12 | 2023 | 80 | 1.010 |
Why?
|
| Quality of Life | 11 | 2022 | 662 | 1.010 |
Why?
|
| Dyskinesias | 6 | 2021 | 35 | 1.000 |
Why?
|
| Surveys and Questionnaires | 21 | 2022 | 1184 | 0.990 |
Why?
|
| Corpus Callosum | 3 | 2018 | 15 | 0.870 |
Why?
|
| Amnesia | 4 | 2012 | 27 | 0.830 |
Why?
|
| Huntington Disease | 5 | 2023 | 60 | 0.810 |
Why?
|
| Nervous System Diseases | 2 | 2020 | 145 | 0.790 |
Why?
|
| Dystonic Disorders | 4 | 2022 | 29 | 0.780 |
Why?
|
| Anticipation, Psychological | 1 | 2020 | 8 | 0.760 |
Why?
|
| Professional-Patient Relations | 1 | 2020 | 28 | 0.740 |
Why?
|
| Placebos | 1 | 2020 | 77 | 0.740 |
Why?
|
| Personality | 1 | 2020 | 68 | 0.710 |
Why?
|
| Nerve Fibers, Myelinated | 6 | 2011 | 39 | 0.710 |
Why?
|
| Voice Disorders | 1 | 2018 | 1 | 0.670 |
Why?
|
| Aged, 80 and over | 25 | 2021 | 4851 | 0.660 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 194 | 0.640 |
Why?
|
| Signal Transduction | 1 | 2020 | 482 | 0.620 |
Why?
|
| Levodopa | 5 | 2023 | 142 | 0.620 |
Why?
|
| Glucosylceramidase | 5 | 2022 | 26 | 0.600 |
Why?
|
| Retinal Vessels | 1 | 2016 | 3 | 0.580 |
Why?
|
| Postural Balance | 3 | 2018 | 121 | 0.580 |
Why?
|
| Fractals | 1 | 2016 | 22 | 0.570 |
Why?
|
| HIV Infections | 3 | 2016 | 970 | 0.570 |
Why?
|
| Antiparkinson Agents | 7 | 2023 | 130 | 0.570 |
Why?
|
| Activities of Daily Living | 11 | 2019 | 501 | 0.550 |
Why?
|
| Disease Progression | 12 | 2022 | 787 | 0.550 |
Why?
|
| Image Processing, Computer-Assisted | 7 | 2017 | 219 | 0.540 |
Why?
|
| Language | 4 | 2021 | 78 | 0.530 |
Why?
|
| Lewy Body Disease | 2 | 2023 | 98 | 0.530 |
Why?
|
| Mental Recall | 2 | 2008 | 74 | 0.530 |
Why?
|
| Neurology | 5 | 2021 | 101 | 0.530 |
Why?
|
| Cognition | 6 | 2023 | 1277 | 0.520 |
Why?
|
| Memory | 6 | 2013 | 318 | 0.520 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 6 | 2010 | 96 | 0.520 |
Why?
|
| Gait Disorders, Neurologic | 2 | 2016 | 144 | 0.510 |
Why?
|
| Sleep | 2 | 2019 | 313 | 0.510 |
Why?
|
| Visual Perception | 2 | 2005 | 50 | 0.510 |
Why?
|
| Entorhinal Cortex | 2 | 2012 | 37 | 0.510 |
Why?
|
| Cross-Sectional Studies | 9 | 2022 | 959 | 0.480 |
Why?
|
| Adult | 24 | 2023 | 8601 | 0.480 |
Why?
|
| Subthalamic Nucleus | 4 | 2022 | 32 | 0.460 |
Why?
|
| Sensation Disorders | 1 | 2013 | 13 | 0.460 |
Why?
|
| Frontal Lobe | 4 | 2011 | 81 | 0.450 |
Why?
|
| Visual Pathways | 3 | 2014 | 8 | 0.450 |
Why?
|
| Supranuclear Palsy, Progressive | 3 | 2020 | 44 | 0.440 |
Why?
|
| Brain Ischemia | 3 | 2010 | 71 | 0.440 |
Why?
|
| Alzheimer Disease | 7 | 2010 | 1942 | 0.430 |
Why?
|
| Dopamine Agonists | 2 | 2011 | 46 | 0.430 |
Why?
|
| Dystonia | 4 | 2023 | 53 | 0.430 |
Why?
|
| Behavioral Symptoms | 3 | 2017 | 13 | 0.400 |
Why?
|
| Cerebral Cortex | 3 | 2014 | 195 | 0.400 |
Why?
|
| Dopamine | 1 | 2011 | 156 | 0.390 |
Why?
|
| Aging | 5 | 2011 | 1593 | 0.380 |
Why?
|
| Multiple System Atrophy | 2 | 2022 | 42 | 0.370 |
Why?
|
| Attention | 5 | 2014 | 144 | 0.350 |
Why?
|
| Factor Analysis, Statistical | 9 | 2023 | 77 | 0.350 |
Why?
|
| Videotape Recording | 5 | 2011 | 43 | 0.340 |
Why?
|
| Mental Disorders | 2 | 2021 | 140 | 0.340 |
Why?
|
| Case-Control Studies | 4 | 2017 | 638 | 0.340 |
Why?
|
| Teaching | 2 | 2009 | 62 | 0.330 |
Why?
|
| Periaqueductal Gray | 1 | 2008 | 2 | 0.330 |
Why?
|
| Brain Mapping | 5 | 2020 | 195 | 0.320 |
Why?
|
| Longitudinal Studies | 10 | 2023 | 1442 | 0.320 |
Why?
|
| Hippocampus | 5 | 2012 | 274 | 0.320 |
Why?
|
| Stroke | 2 | 2010 | 293 | 0.310 |
Why?
|
| Movement | 3 | 2019 | 143 | 0.300 |
Why?
|
| Observer Variation | 5 | 2018 | 118 | 0.290 |
Why?
|
| Mutation | 5 | 2022 | 383 | 0.280 |
Why?
|
| Electrodes, Implanted | 3 | 2017 | 46 | 0.280 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2020 | 379 | 0.280 |
Why?
|
| Botulinum Toxins, Type A | 2 | 2023 | 34 | 0.270 |
Why?
|
| Memory Disorders | 3 | 2014 | 174 | 0.270 |
Why?
|
| Video Recording | 3 | 2022 | 47 | 0.270 |
Why?
|
| Neuromuscular Agents | 2 | 2023 | 19 | 0.260 |
Why?
|
| Evaluation Studies as Topic | 3 | 2010 | 56 | 0.260 |
Why?
|
| Restless Legs Syndrome | 2 | 2014 | 11 | 0.260 |
Why?
|
| Brain Chemistry | 1 | 2005 | 47 | 0.260 |
Why?
|
| Clinical Trials as Topic | 3 | 2019 | 324 | 0.260 |
Why?
|
| Executive Function | 3 | 2014 | 121 | 0.250 |
Why?
|
| Dementia | 4 | 2016 | 521 | 0.250 |
Why?
|
| Pediatrics | 2 | 2014 | 33 | 0.250 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2023 | 34 | 0.250 |
Why?
|
| Heterozygote | 2 | 2022 | 103 | 0.250 |
Why?
|
| Certification | 1 | 2004 | 49 | 0.250 |
Why?
|
| Cohort Studies | 9 | 2018 | 1939 | 0.250 |
Why?
|
| Atrophy | 5 | 2017 | 102 | 0.240 |
Why?
|
| Tic Disorders | 2 | 2017 | 17 | 0.240 |
Why?
|
| Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 | 2 | 2021 | 10 | 0.240 |
Why?
|
| Hemifacial Spasm | 1 | 2023 | 2 | 0.240 |
Why?
|
| Emotions | 3 | 2015 | 90 | 0.230 |
Why?
|
| Databases, Factual | 4 | 2022 | 330 | 0.230 |
Why?
|
| Checklist | 2 | 2022 | 36 | 0.230 |
Why?
|
| Mentors | 1 | 2023 | 47 | 0.230 |
Why?
|
| Cross-Cultural Comparison | 1 | 2023 | 42 | 0.220 |
Why?
|
| Models, Biological | 1 | 2005 | 343 | 0.220 |
Why?
|
| Stereotaxic Techniques | 3 | 2020 | 27 | 0.220 |
Why?
|
| Anisotropy | 5 | 2010 | 58 | 0.220 |
Why?
|
| Advisory Committees | 2 | 2013 | 34 | 0.220 |
Why?
|
| Delphi Technique | 2 | 2020 | 27 | 0.210 |
Why?
|
| Fatigue | 2 | 2014 | 59 | 0.210 |
Why?
|
| Bias | 1 | 2022 | 33 | 0.210 |
Why?
|
| Verbal Learning | 1 | 2002 | 42 | 0.210 |
Why?
|
| Sensitivity and Specificity | 6 | 2019 | 553 | 0.210 |
Why?
|
| Societies, Scientific | 2 | 2012 | 12 | 0.210 |
Why?
|
| Guidelines as Topic | 2 | 2013 | 67 | 0.200 |
Why?
|
| Office Visits | 1 | 2021 | 12 | 0.200 |
Why?
|
| Health Planning Guidelines | 2 | 2013 | 11 | 0.200 |
Why?
|
| Electronics | 1 | 2021 | 9 | 0.200 |
Why?
|
| Medication Adherence | 1 | 2022 | 78 | 0.200 |
Why?
|
| Friedreich Ataxia | 1 | 2020 | 1 | 0.200 |
Why?
|
| Spinocerebellar Ataxias | 1 | 2020 | 2 | 0.200 |
Why?
|
| Cerebellar Ataxia | 1 | 2020 | 6 | 0.190 |
Why?
|
| Regression Analysis | 3 | 2018 | 298 | 0.190 |
Why?
|
| Frontotemporal Dementia | 1 | 2020 | 14 | 0.190 |
Why?
|
| Austria | 1 | 2020 | 5 | 0.190 |
Why?
|
| Follow-Up Studies | 8 | 2017 | 1830 | 0.190 |
Why?
|
| Caregivers | 2 | 2023 | 143 | 0.190 |
Why?
|
| Temporal Lobe | 3 | 2011 | 105 | 0.190 |
Why?
|
| Head | 1 | 2020 | 24 | 0.180 |
Why?
|
| Neck | 1 | 2020 | 33 | 0.180 |
Why?
|
| Thiazolidinediones | 2 | 2010 | 14 | 0.180 |
Why?
|
| Quality Improvement | 1 | 2021 | 158 | 0.180 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 2 | 2010 | 24 | 0.180 |
Why?
|
| Compulsive Behavior | 1 | 2019 | 6 | 0.180 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 1 | 2019 | 10 | 0.180 |
Why?
|
| alpha-Synuclein | 2 | 2021 | 138 | 0.180 |
Why?
|
| Impulsive Behavior | 1 | 2019 | 21 | 0.170 |
Why?
|
| Psychotic Disorders | 2 | 2010 | 43 | 0.170 |
Why?
|
| Time Factors | 7 | 2019 | 1616 | 0.170 |
Why?
|
| Clinical Studies as Topic | 1 | 2019 | 3 | 0.170 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2019 | 12 | 0.170 |
Why?
|
| Diffusion Tensor Imaging | 4 | 2018 | 81 | 0.170 |
Why?
|
| Mobile Applications | 1 | 2019 | 24 | 0.170 |
Why?
|
| Nocebo Effect | 1 | 2018 | 2 | 0.170 |
Why?
|
| Dysphonia | 1 | 2018 | 3 | 0.170 |
Why?
|
| Patient Outcome Assessment | 1 | 2019 | 43 | 0.170 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 389 | 0.170 |
Why?
|
| Laryngoscopy | 1 | 2018 | 21 | 0.170 |
Why?
|
| Wearable Electronic Devices | 1 | 2019 | 40 | 0.170 |
Why?
|
| Dopamine Agents | 2 | 2011 | 40 | 0.160 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2018 | 306 | 0.160 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2019 | 75 | 0.160 |
Why?
|
| Patient Satisfaction | 2 | 2019 | 295 | 0.160 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2008 | 42 | 0.160 |
Why?
|
| Amantadine | 2 | 2017 | 15 | 0.150 |
Why?
|
| Young Adult | 4 | 2018 | 1932 | 0.150 |
Why?
|
| Essential Tremor | 1 | 2016 | 15 | 0.150 |
Why?
|
| Knowledge | 1 | 2016 | 19 | 0.150 |
Why?
|
| White Matter | 1 | 2018 | 149 | 0.150 |
Why?
|
| Anticonvulsants | 1 | 2017 | 109 | 0.140 |
Why?
|
| Veins | 1 | 2016 | 8 | 0.140 |
Why?
|
| Hypokinesia | 2 | 2023 | 27 | 0.140 |
Why?
|
| Arteries | 1 | 2016 | 17 | 0.140 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2016 | 4 | 0.140 |
Why?
|
| Mass Screening | 2 | 2018 | 177 | 0.140 |
Why?
|
| Adolescent | 3 | 2018 | 2279 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2016 | 81 | 0.140 |
Why?
|
| Chronic Disease | 2 | 2010 | 495 | 0.140 |
Why?
|
| Antipsychotic Agents | 3 | 2010 | 82 | 0.140 |
Why?
|
| Substantia Nigra | 1 | 2016 | 148 | 0.140 |
Why?
|
| Amygdala | 1 | 2015 | 50 | 0.130 |
Why?
|
| Blepharospasm | 1 | 2015 | 8 | 0.130 |
Why?
|
| Health Status | 3 | 2013 | 227 | 0.130 |
Why?
|
| Translations | 3 | 2021 | 16 | 0.130 |
Why?
|
| Space Perception | 1 | 2014 | 28 | 0.130 |
Why?
|
| Probability | 1 | 2014 | 94 | 0.130 |
Why?
|
| Feasibility Studies | 5 | 2019 | 227 | 0.130 |
Why?
|
| Interviews as Topic | 1 | 2014 | 130 | 0.120 |
Why?
|
| Blindness | 1 | 2014 | 14 | 0.120 |
Why?
|
| Animals | 5 | 2017 | 4552 | 0.120 |
Why?
|
| Behavior | 1 | 2014 | 27 | 0.120 |
Why?
|
| Prevalence | 3 | 2010 | 487 | 0.120 |
Why?
|
| Psychotherapy, Psychodynamic | 1 | 2013 | 3 | 0.120 |
Why?
|
| Psychotherapy, Brief | 1 | 2013 | 4 | 0.120 |
Why?
|
| Somatoform Disorders | 1 | 2013 | 20 | 0.120 |
Why?
|
| Functional Neuroimaging | 1 | 2013 | 9 | 0.120 |
Why?
|
| Prospective Studies | 3 | 2023 | 1811 | 0.120 |
Why?
|
| Nerve Net | 1 | 2014 | 54 | 0.120 |
Why?
|
| Child | 5 | 2020 | 1346 | 0.120 |
Why?
|
| Sleep Stages | 1 | 2013 | 34 | 0.120 |
Why?
|
| Predictive Value of Tests | 4 | 2021 | 521 | 0.120 |
Why?
|
| Treatment Outcome | 5 | 2023 | 3478 | 0.110 |
Why?
|
| Motor Skills | 2 | 2020 | 61 | 0.110 |
Why?
|
| Cost of Illness | 1 | 2013 | 54 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 144 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 770 | 0.110 |
Why?
|
| ROC Curve | 1 | 2013 | 138 | 0.110 |
Why?
|
| Statistics, Nonparametric | 4 | 2018 | 138 | 0.110 |
Why?
|
| Affect | 2 | 2010 | 64 | 0.110 |
Why?
|
| International Cooperation | 3 | 2018 | 32 | 0.110 |
Why?
|
| Vibration | 1 | 2012 | 26 | 0.100 |
Why?
|
| Weights and Measures | 1 | 2011 | 8 | 0.100 |
Why?
|
| Parahippocampal Gyrus | 1 | 2011 | 5 | 0.100 |
Why?
|
| Hypotension, Orthostatic | 1 | 2011 | 16 | 0.100 |
Why?
|
| Physical Therapy Modalities | 1 | 2012 | 80 | 0.100 |
Why?
|
| Logistic Models | 2 | 2013 | 407 | 0.100 |
Why?
|
| Poland | 2 | 2021 | 6 | 0.100 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2015 | 222 | 0.100 |
Why?
|
| Touch | 2 | 2021 | 11 | 0.100 |
Why?
|
| Implantable Neurostimulators | 1 | 2010 | 14 | 0.100 |
Why?
|
| Survivors | 1 | 2010 | 57 | 0.100 |
Why?
|
| Posture | 2 | 2021 | 78 | 0.090 |
Why?
|
| PPAR gamma | 1 | 2010 | 12 | 0.090 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2010 | 46 | 0.090 |
Why?
|
| Body Weight | 1 | 2010 | 133 | 0.090 |
Why?
|
| Radiography | 2 | 2012 | 678 | 0.090 |
Why?
|
| Illinois | 1 | 2010 | 241 | 0.090 |
Why?
|
| Depressive Disorder | 2 | 2008 | 187 | 0.090 |
Why?
|
| Analysis of Variance | 5 | 2013 | 321 | 0.090 |
Why?
|
| Postoperative Period | 3 | 2017 | 288 | 0.090 |
Why?
|
| Age Factors | 3 | 2021 | 843 | 0.090 |
Why?
|
| Primary Dysautonomias | 1 | 2009 | 5 | 0.090 |
Why?
|
| Caudate Nucleus | 2 | 2004 | 18 | 0.090 |
Why?
|
| Israel | 2 | 2020 | 16 | 0.090 |
Why?
|
| Mental Status Schedule | 3 | 2015 | 113 | 0.090 |
Why?
|
| Tourette Syndrome | 1 | 2009 | 37 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2017 | 437 | 0.080 |
Why?
|
| Neuroprotective Agents | 1 | 2009 | 59 | 0.080 |
Why?
|
| Brief Psychiatric Rating Scale | 1 | 2008 | 8 | 0.080 |
Why?
|
| Double-Blind Method | 3 | 2017 | 503 | 0.080 |
Why?
|
| Photic Stimulation | 2 | 2005 | 44 | 0.080 |
Why?
|
| Motivation | 1 | 2008 | 100 | 0.080 |
Why?
|
| Thalamus | 1 | 2008 | 28 | 0.080 |
Why?
|
| Linear Models | 3 | 2014 | 254 | 0.080 |
Why?
|
| Stroke Rehabilitation | 1 | 2007 | 11 | 0.080 |
Why?
|
| Anxiety Disorders | 1 | 2008 | 168 | 0.080 |
Why?
|
| Motor Cortex | 1 | 2007 | 17 | 0.080 |
Why?
|
| Neurons | 2 | 2020 | 374 | 0.070 |
Why?
|
| Biomarkers | 2 | 2021 | 689 | 0.070 |
Why?
|
| Dominance, Cerebral | 2 | 2007 | 23 | 0.070 |
Why?
|
| Adrenal Medulla | 3 | 1991 | 31 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2023 | 394 | 0.070 |
Why?
|
| Nerve Fibers | 1 | 2006 | 14 | 0.070 |
Why?
|
| Depressive Disorder, Major | 1 | 2007 | 107 | 0.070 |
Why?
|
| Risk Factors | 3 | 2010 | 2443 | 0.070 |
Why?
|
| Socioeconomic Factors | 3 | 2013 | 328 | 0.070 |
Why?
|
| Recovery of Function | 1 | 2007 | 290 | 0.070 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2005 | 16 | 0.070 |
Why?
|
| History, 19th Century | 2 | 2018 | 66 | 0.070 |
Why?
|
| Psychomotor Performance | 3 | 2013 | 216 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2005 | 96 | 0.070 |
Why?
|
| Vision Disorders | 1 | 2005 | 23 | 0.070 |
Why?
|
| Parietal Lobe | 1 | 2004 | 21 | 0.060 |
Why?
|
| Gyrus Cinguli | 1 | 2004 | 22 | 0.060 |
Why?
|
| Corpus Striatum | 2 | 2019 | 111 | 0.060 |
Why?
|
| Motor Activity | 1 | 2007 | 369 | 0.060 |
Why?
|
| Inosine | 1 | 2022 | 5 | 0.060 |
Why?
|
| Consensus | 1 | 2023 | 105 | 0.060 |
Why?
|
| Learning | 1 | 2023 | 79 | 0.060 |
Why?
|
| Canada | 2 | 2021 | 56 | 0.060 |
Why?
|
| Uric Acid | 1 | 2022 | 13 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2022 | 39 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2021 | 3273 | 0.050 |
Why?
|
| Semantics | 1 | 2002 | 20 | 0.050 |
Why?
|
| Anxiety | 1 | 2023 | 152 | 0.050 |
Why?
|
| Arousal | 1 | 2002 | 42 | 0.050 |
Why?
|
| Computers | 1 | 2022 | 26 | 0.050 |
Why?
|
| Finland | 1 | 2021 | 6 | 0.050 |
Why?
|
| Rehabilitation | 1 | 2021 | 14 | 0.050 |
Why?
|
| Insurance, Health | 1 | 2021 | 22 | 0.050 |
Why?
|
| Walking Speed | 1 | 2022 | 41 | 0.050 |
Why?
|
| Organ Size | 2 | 2012 | 107 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2011 | 145 | 0.050 |
Why?
|
| Models, Theoretical | 1 | 2021 | 91 | 0.050 |
Why?
|
| Phenotype | 1 | 2022 | 355 | 0.050 |
Why?
|
| Constipation | 2 | 2011 | 21 | 0.050 |
Why?
|
| PubMed | 2 | 2011 | 12 | 0.050 |
Why?
|
| Microelectrodes | 1 | 2020 | 36 | 0.050 |
Why?
|
| Prognosis | 2 | 2021 | 840 | 0.050 |
Why?
|
| Fingers | 1 | 2020 | 10 | 0.050 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 208 | 0.050 |
Why?
|
| Choline O-Acetyltransferase | 1 | 1999 | 14 | 0.050 |
Why?
|
| Prosencephalon | 1 | 1999 | 8 | 0.050 |
Why?
|
| Quality of Health Care | 1 | 2021 | 138 | 0.050 |
Why?
|
| Ataxia | 1 | 2020 | 79 | 0.040 |
Why?
|
| Registries | 2 | 1991 | 188 | 0.040 |
Why?
|
| Personal Satisfaction | 1 | 2019 | 47 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2019 | 17 | 0.040 |
Why?
|
| Databases, Bibliographic | 1 | 2018 | 11 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 75 | 0.040 |
Why?
|
| History, 18th Century | 1 | 2018 | 8 | 0.040 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2018 | 6 | 0.040 |
Why?
|
| Phylogeny | 2 | 2015 | 63 | 0.040 |
Why?
|
| Exercise | 1 | 2023 | 468 | 0.040 |
Why?
|
| Nevada | 1 | 2017 | 1 | 0.040 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 86 | 0.040 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 89 | 0.040 |
Why?
|
| Patient Advocacy | 1 | 2017 | 14 | 0.040 |
Why?
|
| Translating | 1 | 2017 | 5 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 236 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2010 | 642 | 0.040 |
Why?
|
| Seveso Accidental Release | 1 | 2017 | 2 | 0.040 |
Why?
|
| Ventral Thalamic Nuclei | 1 | 2017 | 3 | 0.040 |
Why?
|
| Pain | 1 | 2021 | 391 | 0.040 |
Why?
|
| Globus Pallidus | 1 | 2017 | 31 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 2017 | 44 | 0.040 |
Why?
|
| Olfactory Bulb | 1 | 2016 | 16 | 0.040 |
Why?
|
| Locus Coeruleus | 1 | 2016 | 23 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2016 | 78 | 0.040 |
Why?
|
| Reference Values | 2 | 2007 | 227 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 86 | 0.030 |
Why?
|
| Superior Colliculi | 1 | 2014 | 2 | 0.030 |
Why?
|
| Genotype | 1 | 2015 | 405 | 0.030 |
Why?
|
| Botulinum Toxins | 1 | 2014 | 32 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2013 | 78 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2013 | 113 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2013 | 64 | 0.030 |
Why?
|
| Sample Size | 1 | 2013 | 25 | 0.030 |
Why?
|
| alpha-Amylases | 1 | 1992 | 3 | 0.030 |
Why?
|
| Lewy Bodies | 1 | 2014 | 195 | 0.030 |
Why?
|
| Plants | 1 | 1992 | 9 | 0.030 |
Why?
|
| Observation | 1 | 2012 | 16 | 0.030 |
Why?
|
| Calibration | 1 | 2012 | 22 | 0.030 |
Why?
|
| Italy | 1 | 2012 | 16 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2012 | 29 | 0.030 |
Why?
|
| Biological Evolution | 1 | 1992 | 23 | 0.030 |
Why?
|
| Skull | 1 | 2012 | 25 | 0.030 |
Why?
|
| Benzoxazoles | 1 | 2011 | 2 | 0.030 |
Why?
|
| Urinary Bladder Diseases | 1 | 2011 | 8 | 0.030 |
Why?
|
| Benzothiazoles | 1 | 2011 | 20 | 0.030 |
Why?
|
| Sickness Impact Profile | 1 | 2011 | 19 | 0.030 |
Why?
|
| United States | 2 | 2015 | 2333 | 0.020 |
Why?
|
| Norway | 1 | 2010 | 2 | 0.020 |
Why?
|
| Piperazines | 1 | 2011 | 90 | 0.020 |
Why?
|
| Polysomnography | 1 | 2010 | 92 | 0.020 |
Why?
|
| Community Health Planning | 1 | 2010 | 21 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2010 | 26 | 0.020 |
Why?
|
| Transplantation, Heterotopic | 1 | 1990 | 12 | 0.020 |
Why?
|
| Synaptic Transmission | 1 | 2010 | 46 | 0.020 |
Why?
|
| Mood Disorders | 1 | 2010 | 31 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2010 | 132 | 0.020 |
Why?
|
| Algorithms | 1 | 2012 | 400 | 0.020 |
Why?
|
| Alleles | 1 | 2010 | 224 | 0.020 |
Why?
|
| Illusions | 1 | 2009 | 4 | 0.020 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2009 | 16 | 0.020 |
Why?
|
| Neurotransmitter Agents | 1 | 2009 | 20 | 0.020 |
Why?
|
| Sialorrhea | 1 | 2009 | 5 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 96 | 0.020 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2009 | 23 | 0.020 |
Why?
|
| Computer-Aided Design | 1 | 2009 | 16 | 0.020 |
Why?
|
| Deglutition Disorders | 1 | 2009 | 44 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2011 | 462 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2009 | 81 | 0.020 |
Why?
|
| Delusions | 1 | 2008 | 12 | 0.020 |
Why?
|
| Apolipoprotein E4 | 1 | 2010 | 227 | 0.020 |
Why?
|
| Depression | 1 | 2012 | 465 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2010 | 428 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2008 | 150 | 0.020 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2007 | 17 | 0.020 |
Why?
|
| Dementia, Vascular | 1 | 2007 | 41 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 2009 | 668 | 0.020 |
Why?
|
| Neural Pathways | 1 | 2007 | 83 | 0.020 |
Why?
|
| Syndrome | 1 | 2006 | 82 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2006 | 39 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2007 | 324 | 0.020 |
Why?
|
| Cerebral Infarction | 1 | 2007 | 152 | 0.020 |
Why?
|
| Photography | 1 | 2005 | 17 | 0.020 |
Why?
|
| Pattern Recognition, Visual | 1 | 2005 | 31 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2004 | 84 | 0.020 |
Why?
|
| Ovariectomy | 1 | 1999 | 26 | 0.010 |
Why?
|
| Organ Specificity | 1 | 1999 | 47 | 0.010 |
Why?
|
| Estrogen Receptor alpha | 1 | 1999 | 15 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 1999 | 58 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 1999 | 391 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1999 | 451 | 0.010 |
Why?
|
| Rats | 1 | 1999 | 854 | 0.010 |
Why?
|
| Poaceae | 1 | 1992 | 5 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1992 | 10 | 0.010 |
Why?
|
| Base Sequence | 1 | 1992 | 134 | 0.010 |
Why?
|
| DNA | 1 | 1992 | 125 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1992 | 246 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1992 | 161 | 0.010 |
Why?
|
| Data Collection | 1 | 1991 | 107 | 0.010 |
Why?
|
| Forms and Records Control | 1 | 1990 | 10 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 1990 | 195 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 1990 | 364 | 0.010 |
Why?
|
| Chicago | 1 | 1990 | 865 | 0.000 |
Why?
|